HCP
NBIX icon

Hexagon Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History

Hexagon Capital Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-75
Closed -$7.59K – 1466
2023
Q1 		$7.59K Buy
75
+5
+7% +$520 ﹤0.01% 801
2022
Q4 		$8.36K Sell
70
-25
-26% -$2.93K ﹤0.01% 770
2022
Q3 		$10K Buy
+95
New +$9.64K ﹤0.01% 776

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Hexagon Capital Partners's NBIX Position: Q2 2023 in Review

Hexagon Capital Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 75 shares — an estimated $7.59K sold.

Hexagon Capital Partners first reported a position in NBIX in Q3 2022 and held it in 3 quarters. The position peaked at $10K in Q3 2022. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

  • Hexagon Capital Partners reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
  • Hexagon Capital Partners sold 75 Neurocrine Biosciences shares in Q2 2023, an estimated $7.59K.
  • Hexagon Capital Partners first reported a position in Neurocrine Biosciences in Q3 2022 and held it in 3 quarters.
  • Hexagon Capital Partners's Neurocrine Biosciences position peaked at $10K in Q3 2022.
  • 456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on Hexagon Capital Partners's 13F filing for Q2 2023, filed 24 Jul 2023.